Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 27.24
+1.75 (6.87%)
Sep 30, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,465 | 1,373 | 1,376 | 1,284 | 3,565 | 1,865 |
Other Revenue | 7.47 | 4.99 | 2.31 | 2.41 | 3.81 | 3.78 |
| 1,472 | 1,378 | 1,378 | 1,286 | 3,569 | 1,869 | |
Revenue Growth | 10.28% | -0.00% | 7.15% | -63.97% | 91.00% | 19.44% |
Cost of Revenue | 491.65 | 457.67 | 437.47 | 514.89 | 1,393 | 389.97 |
Gross Profit | 980.46 | 920.21 | 940.43 | 771.1 | 2,176 | 1,479 |
Selling, General & Admin | 748.53 | 724.11 | 722.83 | 708.87 | 818.98 | 499.3 |
Research & Development | 291.09 | 280.67 | 300.39 | 338.62 | 396.11 | 230.32 |
Other Operating Expenses | 23.23 | 8.31 | 9.8 | 2.42 | 19.28 | 7.05 |
Operating Expenses | 1,075 | 1,032 | 1,053 | 1,043 | 1,326 | 748.74 |
Operating Income | -94.79 | -111.66 | -112.85 | -271.53 | 850.23 | 729.91 |
Interest Expense | -22.5 | -24.17 | -27.25 | -35.07 | -12.48 | -3.86 |
Interest & Investment Income | 22.95 | 22.9 | 22.73 | 60.24 | 65.42 | 27.15 |
Currency Exchange Gain (Loss) | -10.08 | 3.37 | -1.99 | 3.18 | 5.04 | -2.32 |
Other Non Operating Income (Expenses) | -4.12 | -1.08 | -7.52 | -3.91 | -45.03 | -0.88 |
EBT Excluding Unusual Items | -108.54 | -110.63 | -126.88 | -247.09 | 863.18 | 750 |
Gain (Loss) on Sale of Investments | 51.62 | 52.59 | 55.36 | 43.04 | 45.9 | 5.83 |
Gain (Loss) on Sale of Assets | 0.13 | -0.29 | -2.1 | 5.67 | -0.64 | -2.34 |
Asset Writedown | -0.42 | -0.42 | -1.8 | -1.73 | -204.23 | - |
Other Unusual Items | 25.56 | 21.05 | 17.16 | 84.39 | -94.82 | 10.96 |
Pretax Income | -31.65 | -37.71 | -58.25 | -115.71 | 609.39 | 764.45 |
Income Tax Expense | -12.95 | -15.2 | -38.63 | -42.85 | 15.88 | 86.16 |
Earnings From Continuing Operations | -18.7 | -22.51 | -19.62 | -72.86 | 593.51 | 678.29 |
Minority Interest in Earnings | 9.92 | 5.89 | 1.53 | 1.91 | 0.74 | - |
Net Income | -8.78 | -16.61 | -18.09 | -70.96 | 594.25 | 678.29 |
Net Income to Common | -8.78 | -16.61 | -18.09 | -70.96 | 594.25 | 678.29 |
Net Income Growth | - | - | - | - | -12.39% | -17.46% |
Shares Outstanding (Basic) | 573 | 539 | 470 | 512 | 518 | 472 |
Shares Outstanding (Diluted) | 573 | 539 | 470 | 512 | 518 | 472 |
Shares Change | 39.58% | 14.77% | -8.27% | -1.18% | 9.95% | 1.96% |
EPS (Basic) | -0.02 | -0.03 | -0.04 | -0.14 | 1.15 | 1.44 |
EPS (Diluted) | -0.02 | -0.03 | -0.04 | -0.14 | 1.15 | 1.44 |
EPS Growth | - | - | - | - | -20.32% | -19.04% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 216.16 | 185.77 | -84.58 | -79.91 | -227.69 | 354.84 |
Free Cash Flow Per Share | 0.38 | 0.34 | -0.18 | -0.16 | -0.44 | 0.75 |
Dividend Per Share | 0.385 | 0.385 | 0.139 | 0.077 | 0.962 | 0.300 |
Dividend Growth | 233.28% | 177.69% | 80.10% | -92.00% | 220.50% | - |
Gross Margin | 66.60% | 66.78% | 68.25% | 59.96% | 60.98% | 79.13% |
Operating Margin | -6.44% | -8.10% | -8.19% | -21.12% | 23.82% | 39.06% |
Profit Margin | -0.60% | -1.21% | -1.31% | -5.52% | 16.65% | 36.30% |
Free Cash Flow Margin | 14.68% | 13.48% | -6.14% | -6.21% | -6.38% | 18.99% |
EBITDA | -5.44 | -19.75 | -2.9 | -173.87 | 913.6 | 761.17 |
EBITDA Margin | -0.37% | -1.43% | -0.21% | -13.52% | 25.60% | 40.73% |
D&A For EBITDA | 89.35 | 91.91 | 109.94 | 97.66 | 63.37 | 31.26 |
EBIT | -94.79 | -111.66 | -112.85 | -271.53 | 850.23 | 729.91 |
EBIT Margin | -6.44% | -8.10% | -8.19% | -21.11% | 23.82% | 39.06% |
Effective Tax Rate | - | - | - | - | 2.61% | 11.27% |
Revenue as Reported | 1,472 | 1,378 | 1,378 | 1,286 | 3,569 | 1,869 |